Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | TTK | P33981 | 1/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.41 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.37 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.37 |
| ▸ | MTOR | P42345 | 1/20 | 0.37 |
| ▸ | NOS3 | P29474 | 3/20 | 0.37 |
| ▸ | NOS1 | P29475 | 3/20 | 0.37 |
| ▸ | NOS2 | P35228 | 3/20 | 0.37 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.35 |
| ▸ | HBB | P68871 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL114703 | 0.98 | MAPT (0.41) | MAPTCASP1AURKATTKAURKB | |
| SCHEMBL8986074 | 0.80 | MAPT (0.56) | MAPTCASP1AURKATTKAURKB | |
| SCHEMBL29540711 | 0.80 | MAPT (0.56) | MAPTCASP1AURKATTKAURKB | |
| SCHEMBL22009627 | 0.79 | KDM4E (0.44) | NOS3NOS1NOS2UHRF1KDM4E | |
| SCHEMBL29716171 | 0.79 | KDM4E (0.44) | NOS3NOS1NOS2UHRF1KDM4E | |
| SCHEMBL3378270 | 0.79 | TSHR (0.38) | MAPTNOS3NOS1NOS2UHRF1 | |
| SCHEMBL14910166 | 0.79 | TSHR (0.40) | PIK3CAMTORNOS3NOS1NOS2 | |
| SCHEMBL14910163 | 0.79 | NOS3 (0.31) | MAPTCASP1NOS3NOS1NOS2 | |
| Hydrochloric Acid SCHEMBL8986081 | 0.78 | MAPT (0.55) | MAPTCASP1AURKATTKAURKB | |
| SCHEMBL115432 | 0.78 | PIK3CA (0.42) | MAPTCASP1AURKATTKAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260098024-A1 | PARP1 INHIBITORS AND USES THEREOF | XINTHERA INC (US) | 2026-04-09 | — | — | US | disclosed |
| US-12338226-B2 | Substituted benzodiazoles and use thereof in therapy | THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING (SE) | 2025-06-24 | — | — | US | disclosed |
| US-20250059181-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | NOVARTIS AG (CH) | 2025-02-20 | — | — | US | disclosed |
| EP-4469449-A1 | PARP1 INHIBITORS AND USES THEREOF | Xinthera, Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| US-20240360075-A1 | N-SUBSTITUTED C6 CYCLYL CARBOXAMIDE COMPOUNDS AND USES THEREOF | ALCON INC. (CH) | 2024-10-31 | — | — | US | disclosed |
| WO-2024220626-A1 | SMALL MOLECULE MODULATORS OF OGG1 | AZKARRA THERAPEUTICS, INC. (US) | 2024-10-24 | — | — | WO | disclosed |
| WO-2024220876-A1 | N-SUBSTITUTED C6 CYCLYL CARBOXAMIDE COMPOUNDS AND USES THEREOF | ALCON INC. (CH) | 2024-10-24 | — | — | WO | disclosed |
| US-20240287020-A1 | SUBSTITUTED BENZODIAZOLES AND USE THEREOF IN THERAPY | THOMAS HELLEDAYS STIFTELSE FÖR MEDICINSK FORSKNING (SE) | 2024-08-29 | — | — | US | disclosed |
| CN-118510767-A | PARP1 inhibitors and uses thereof | 新特拉有限公司 | 2024-08-16 | — | — | CN | disclosed |
| US-11970474-B2 | Substituted benzodiazoles and use thereof in therapy | THOMAS HELLEDAYS STIFTELSE FÖR MEDICINSK FORSKNING (SE) | 2024-04-30 | — | — | US | disclosed |
| US-20090054410-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2009-02-26 | — | — | US | disclosed |
| US-7470705-B2 | e.g. Cis-4-[acety1-(3,5-bis-trifluoromethyl-benzyl)-amino]-2-ethyl-6-methoxy-3,4-dihydro-2H- [1,5]naphthyridine-1-carboxylic acid isopropyl ester; cholesterol ester transfer protein (CETP) inhibitors; increasing plasma HDL- cholesterol, decreasing plasma LDL- cholesterol; atherosclerosis | ELI LILLY AND COMPANY (US) | 2008-12-30 | — | — | US | disclosed |
| US-7470705-B2 | e.g. Cis-4-[acety1-(3,5-bis-trifluoromethyl-benzyl)-amino]-2-ethyl-6-methoxy-3,4-dihydro-2H- [1,5]naphthyridine-1-carboxylic acid isopropyl ester; cholesterol ester transfer protein (CETP) inhibitors; increasing plasma HDL- cholesterol, decreasing plasma LDL- cholesterol; atherosclerosis | ELI LILLY AND COMPANY (US) | 2008-12-30 | — | — | US | disclosed |
| EP-1737862-A4 | IMIDAZOPYRIDINE COMPOUND | EISAI R&D MAN CO LTD (JP) | 2007-11-28 | — | — | EP | disclosed |
| US-20070173526-A1 | Compounds and methods for treating dyslipidemia | ELI LILLY AND COMPANY (US) | 2007-07-26 | — | — | US | disclosed |
| US-20070173526-A1 | Compounds and methods for treating dyslipidemia | ELI LILLY AND COMPANY (US) | 2007-07-26 | — | — | US | disclosed |
| EP-1737862-A1 | IMIDAZOPYRIDINE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2007-01-03 | — | — | EP | disclosed |
| US-20060167041-A1 | such as 5-(4-Fluorophenoxy)-2-(((4-methoxy-3-methyl-2-pyridinyl)methyl)sulfinyl)-3H-imidazo[4,5-b]pyridine, useful as a gastric acid secretion inhibitor, for the treatment of gastroesophageal reflux or ulcers; antisecretory agents | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2006-07-27 | — | — | US | disclosed |
| US-20050272764-A1 | Imidazopyridine compound | EISAI CO., LTD. | 2005-12-08 | — | — | US | disclosed |
| WO-2005103049-A1 | IMIDAZOPYRIDINE COMPOUND | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2005-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272764-A1 | Imidazopyridine compound | H1-3, KCNH2, H1-4 | MAPT 2665/4885CASP1 992/4885AURKA 395/4885 |
| US-20240360075-A1 | N-SUBSTITUTED C6 CYCLYL CARBOXAMIDE COMPOUNDS AND USES THEREOF | TRPM8, TRPM7, TRPM2 | MAPT 2463/4885CASP1 139/4885AURKA 933/4885 |
| US-20070173526-A1 | Compounds and methods for treating dyslipidemia | PCSK9, APOB, LIPC | MAPT 4690/4885CASP1 2737/4885AURKA 2365/4885 |
| US-20260098024-A1 | PARP1 INHIBITORS AND USES THEREOF | PARP1, PARP11, PARP16 | MAPT 4526/4885CASP1 892/4885AURKA 430/4885 |
| US-20250059181-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | PIK3CA, TYMP, TYMS | MAPT 2283/4885CASP1 1917/4885AURKA 2107/4885 |
| US-11970474-B2 | Substituted benzodiazoles and use thereof in therapy | XDH, CYP4X1, CYP11B2 | MAPT 2969/4885CASP1 450/4885AURKA 3298/4885 |
| US-20240287020-A1 | SUBSTITUTED BENZODIAZOLES AND USE THEREOF IN THERAPY | XDH, CYP11B2, CYP4X1 | MAPT 2943/4885CASP1 475/4885AURKA 3772/4885 |
| US-20060167041-A1 | such as 5-(4-Fluorophenoxy)-2-(((4-methoxy-3-methyl-2-pyridinyl)methyl)sulfinyl)-3H-imidazo[4,5-b]pyridine, useful as a gastric acid secretion inhibitor, for the treatment of gastroesophageal reflux or ulcers; antisecretory agents | HRH2, HRH4, GRPR | MAPT 4820/4885CASP1 1417/4885AURKA 4190/4885 |
| US-20090054410-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | MAPT 9/4885CASP1 1177/4885AURKA 3655/4885 |
| US-12338226-B2 | Substituted benzodiazoles and use thereof in therapy | XDH, CYP11B2, CYP4X1 | MAPT 2943/4885CASP1 475/4885AURKA 3772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.